Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
A number of TP53-MDM2 inhibitors are currently under investigation as therapeutic agents in a variety of clinical trials in patients with TP53 wild type tumors. Not all wild type TP53 tumors are sensitive to such inhibitors. In an attempt to improve selection of patients with TP53 wild type tumors,...
| Váldodahkki: | |
|---|---|
| Materiálatiipa: | Artihkal |
| Giella: | English |
| Almmustuhtton: |
eLife Sciences Publications Ltd
2015-10-01
|
| Ráidu: | eLife |
| Fáttát: | |
| Liŋkkat: | https://elifesciences.org/articles/10279 |